Liver protective effects of quercetin

Excerpt:


J Pharm Pharmacogn Res 7(3): 200-212, 2019. DOI: https://doi.org/10.56499/jppres19.610_7.3.200 Original Article Quercetin through mitigation of inflammatory response and oxidative stress exerts protective effects in rat model of diclofenac-induced liver toxicity [Efectos protectores de quercetina mediante la mitigación de la respuesta inflamatoria y el estrés oxidativo sobre la toxicidad hepática inducida por diclofenaco en ratas] Ali Nouri1, Esfandiar … Continue reading Liver protective effects of quercetin

J Pharm Pharmacogn Res 7(3): 200-212, 2019.

DOI: https://doi.org/10.56499/jppres19.610_7.3.200

Original Article

Quercetin through mitigation of inflammatory response and oxidative stress exerts protective effects in rat model of diclofenac-induced liver toxicity

[Efectos protectores de quercetina mediante la mitigación de la respuesta inflamatoria y el estrés oxidativo sobre la toxicidad hepática inducida por diclofenaco en ratas]

Ali Nouri1, Esfandiar Heidarian1, Hossein Amini-khoei2, Saber Abbaszadeh3,4, Gholam Basati5*

1Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
2Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
3Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
4Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
5Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.

*E-mail: majidas102@yahoo.com

Abstract

Context: Diclofenac (DIC) is known for its anti-inflammatory and analgesic properties but liver toxicity is one of the main targets to use this drug. Previous studies have demonstrated that quercetin may decrease the toxicity of synthetic drugs.

Aim: To assess the protective effect of quercetin against DIC-induced liver toxicity in rats.

Methods: The rats exposed to DIC (50 mg/kg; i.p.) were treated with different doses of quercetin (20, 40 and 80 mg/kg). The levels of glutathione peroxidase (GPx), superoxide dismutase (SOD), intracellular glutathione (GSH) and catalase (CAT) in the liver tissue were assessed.

Results: Results indicated a significant decline in above-mentioned factors in DIC-alone treated group compared to the control group. Also, levels of the triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), total bilirubin, alkaline phosphatase (ALP), nitrite content, alanine aminotransferase (ALT), malondialdehyde (MDA), serum tumor necrosis factor-α (TNF-α), serum interleukin-1β (IL-1β),  aspartate aminotransferase (AST), and inflammatory cytokines were evaluated and results indicted remarkable elevation in these factors in DIC-alone treated group compared to the  control group. Treatment with quercetin caused a significant elevation in GPx, SOD, GSH, CAT and a significant reduction in levels of TG, TC, LDL-C, VLDL-C, total bilirubin, ALP, nitrite content, ALT, MDA, serum TNF-α, serum IL-1β, AST and inflammatory cytokines in DIC-alone treated group compared to the  control group (p<0.05). Histopathological alterations were also improved following quercetin administration.

Conclusions: Quercetin may exert a protective effect against DIC-induced liver toxicity in rats through mitigation of oxidative stress and inflammatory response.

Keywords: diclofenac; IL-1β; liver toxicity; oxidative stress; quercetin; TNF-α.

Resumen

Contexto: El diclofenaco (DIC) posee propiedades antiinflamatorias y analgésicas, pero produce toxicidad hepática. Estudios anteriores han demostrado que la quercetina (Q) puede disminuir la toxicidad de los fármacos sintéticos.

Objetivo: Evaluar el efecto protector de la Q contra la toxicidad hepática inducida por DIC en ratas.

Métodos: Las ratas expuestas a DIC (50 mg/kg; i.p.) se trataron con diferentes dosis de Q (20, 40 y 80 mg/kg). Se evaluaron los niveles de glutatión peroxidasa (GPx), superóxido dismutasa (SOD), glutatión intracelular (GSH) y catalasa (CAT) en el tejido hepático.

Resultados: Se detectó una disminución significativa en los factores mencionados anteriormente en el grupo tratado con DIC solo en comparación con el grupo control. Además, los niveles de triglicéridos (TG), colesterol total (TC), lipoproteínas de baja densidad (LDL-C), lipoproteínas de muy baja densidad (VLDL-C), bilirrubina total, fosfatasa alcalina (ALP), contenido de nitritos, alanina aminotransferasa (ALT), malondialdehído (MDA), factor de necrosis tumoral sérica (TNF-α), interleucina-1β (IL-1β) sérica, aspartato aminotransferasa (AST) y citocinas inflamatorias fueron evaluadas y los resultados indicaron una notable elevación en estas factores en el grupo tratado con DIC en comparación con el grupo control. El tratamiento con Q causó una elevación significativa en GPx, SOD, GSH, CAT y una reducción significativa en los niveles de TG, TC, LDL-C, VLDL-C, bilirrubina total, ALP, contenido de nitrito, ALT, MDA, suero TNF-α, IL-1β en suero, AST y citocinas inflamatorias en el grupo tratado con DIC solo en comparación con el grupo control (p<0.05). Las alteraciones histopatológicas también mejoraron después de la administración de Q.

Conclusiones: La Q ejerce un efecto protector contra la toxicidad hepática inducida por DIC en ratas mediante la mitigación del estrés oxidativo y la respuesta inflamatoria.

Palabras Clave: diclofenaco; estrés oxidativo; IL-1β; quercetina; TNF-α; toxicidad hepática.

Download the PDF file .

Citation Format: Nouri A, Heidarian E, Amini-Khoei H, Abbaszadeh S, Basati G (2019) Quercetin through mitigation of inflammatory response and oxidative stress exerts protective effects in rat model of diclofenac-induced liver toxicity. J Pharm Pharmacogn Res 7(3): 200–212. DOI: https://doi.org/10.56499/jppres19.610_7.3.200

© 2019 Journal of Pharmacy & Pharmacognosy Research (JPPRes)

Periodontal disease in people with HIV infection
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 27-45, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1941_13.1.27 Review Research trends in periodontal disease in people with HIV infection: A bibliometric analysis [Tendencias de investigación en enfermedad periodontal en personas con infección por VIH: Un análisis bibliométrico] Roberto Ojeda-Gómez1*, Julio C. Romero-Gamboa1, Melissa Pineda-Vega1, Pablo A. Millones-Gómez1, John E. … Continue reading Periodontal disease in people with HIV infection
Anti-dormant mycobacterial of marine-derived fungi
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 16-26, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1953_13.1.16 Original Article Activity of ethyl acetate extracts of marine-derived fungi against active and hypoxia-induced dormant Mycobacterium [Actividad de extractos de acetato de etilo de hongos de origen marino contra Mycobacterium latente activa e inducida por hipoxia] Muhammad Azhari1, Atik Pereztia Litanjuasari1, … Continue reading Anti-dormant mycobacterial of marine-derived fungi
Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 1-15, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1967_13.1.1 Original Article In silico study of RNA polymerase inhibitor drugs for Rift Valley fever virus using RdRp protein as the target [Estudio in silico de fármacos inhibidores de la ARN polimerasa para el virus de la fiebre del valle del Rift … Continue reading Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio